IBIO: Long-acting antibody pipeline targets obesity gaps, with IND filings and first-in-human trials ahead

Management outlined a portfolio of long-acting antibody programs targeting obesity and related diseases, leveraging AI-driven discovery and a dual Australia-U.S. regulatory path. Key milestones include IND filings, first-in-human trials, and strategic partnerships, supported by a strong cash position.

Based on iBio, Inc. [IBIO] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 4 2025